A new clinical tool developed by a team of researchers led by the Dana-Farber Cancer Institute pinpoints which Clonal hematopoiesis patients are at highest risk for cancer progression. Their work was published this week in the New England Journal of Medicine Evidence.
“We’ve been able to detect clonal hematopoiesis in patients for years now,” said Dana-Farber hematologist-oncologist and lead author Lachelle D. Weeks, MD, PhD. “But this diagnosis often exposes patients to stress and anxiety because it’s unclear who is at highest risk of developing blood cancer. Our tool can help change that.”
